Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

Stock Information for Tonix Pharmaceuticals Holding Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025
Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
Tonix Pharmaceuticals Launches TONIX ONE(TM), a Fully-Integrated Digital Platform Designed to Help Patients Better Understand and Manage Their Migraine Condition
Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.